Cancer Cachexia: Are We Ready to Take a Step Forward?

被引：7

作者：

Crawford, Jeffrey ^{[1
]}

机构：

[1] Duke Canc Inst, Solid Tumor Therapeut Program, DUMC Box 3476, Durham, NC 27710 USA

来源：

CANCER | 2018年 / 124卷 / 03期

关键词：

CELL LUNG-CANCER; BODY-MASS; TRIALS; ANAMORELIN;

D O I：

10.1002/cncr.31126

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：456 / 458

页数：3

共 14 条

[1]

Bonomi P, 2015, PAPER PRESENTED AT 1

[2] Study Design and Rationale for the Phase 3 Clinical Development Program of Enobosarm, a Selective Androgen Receptor Modulator, for the Prevention and Treatment of Muscle Wasting in Cancer Patients (POWER Trials) [J].

Crawford, Jeffrey ;

Prado, Carla M. M. ;

Johnston, Mary Ann ;

Gralla, Richard J. ;

Taylor, Ryan P. ;

Hancock, Michael L. ;

Dalton, James T. .

CURRENT ONCOLOGY REPORTS, 2016, 18 (06)

[3] ROMANA 3: a phase 3 safety extension study of anamorelin in advanced non-small-cell lung cancer (NSCLC) patients with cachexia [J].

Currow, D. ;

Temel, J. S. ;

Abernethy, A. ;

Milanowski, J. ;

Friend, J. ;

Fearon, K. C. .

ANNALS OF ONCOLOGY, 2017, 28 (08) :1949-1956

[4] Request for regulatory guidance for cancer cachexia intervention trials [J].

Fearon, K. C. H. ;

Argiles, J. M. ;

Baracos, V. E. ;

Bernabei, R. ;

Coats, A. J. S. ;

Crawford, J. ;

Deutz, N. E. ;

Doehner, W. ;

Evans, W. J. ;

Ferrucci, L. ;

Garcia, J. M. ;

Gralla, R. J. ;

Jatoi, A. ;

Kalantar-Zadeh, K. ;

Lainscak, M. ;

Morley, J. E. ;

Muscaritoli, M. ;

Polkey, M. I. ;

Rosano, G. ;

Rossi-Fanelli, F. ;

Schols, A. M. ;

Strasser, F. ;

Vellas, B. ;

von Haehling, S. ;

Anker, S. D. .

JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE, 2015, 6 (04) :272-274

[5] Definition and classification of cancer cachexia: an international consensus [J].

Fearon, Kenneth ;

Strasser, Florian ;

Anker, Stefan D. ;

Bosaeus, Ingvar ;

Bruera, Eduardo ;

Fainsinger, Robin L. ;

Jatoi, Aminah ;

Loprinzi, Charles ;

MacDonald, Neil ;

Mantovani, Giovanni ;

Davis, Mellar ;

Muscaritoli, Maurizio ;

Ottery, Faith ;

Radbruch, Lukas ;

Ravasco, Paula ;

Walsh, Declan ;

Wilcock, Andrew ;

Kaasa, Stein ;

Baracos, Vickie E. .

LANCET ONCOLOGY, 2011, 12 (05) :489-495

[6] Cachexia in patients with cancer [J].

Jafri, Syed H. .

LANCET ONCOLOGY, 2016, 17 (06) :E220-E221

[7] Anamorelin (ONO-7643) for the Treatment of Patients With Non-Small Cell Lung Cancer and Cachexia: Results From a Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Japanese Patients (ONO-7643-04) [J].

Katakami, Nobuyuki ;

Uchino, Junji ;

Yokoyama, Takuma ;

Naito, Tateaki ;

Kondo, Masashi ;

Yamada, Kouzo ;

Kitajima, Hiromoto ;

Yoshimori, Kozo ;

Sato, Kazuhiro ;

Saito, Hiroshi ;

Aoe, Keisuke ;

Tsuji, Tetsuya ;

Takiguchi, Yuichi ;

Takayama, Koichi ;

Komura, Naoyuki ;

Takiguchi, Toru ;

Eguchi, Kenji .

CANCER, 2018, 124 (03) :606-616

[8] Computed tomography-defined muscle and fat wasting are associated with cancer clinical outcomes [J].

Kazemi-Bajestani, Seyyed Mohammad Reza ;

Mazurak, Vera C. ;

Baracos, Vickie .

SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY, 2016, 54 :2-10

[9] Cancer Cachexia in the Age of Obesity: Skeletal Muscle Depletion Is a Powerful Prognostic Factor, Independent of Body Mass Index [J].

Martin, Lisa ;

Birdsell, Laura ;

MacDonald, Neil ;

Reiman, Tony ;

Clandinin, M. Thomas ;

McCargar, Linda J. ;

Murphy, Rachel ;

Ghosh, Sunita ;

Sawyer, Michael B. ;

Baracos, Vickie E. .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (12) :1539-1547

[10] Pharmacology of manipulating lean body mass [J].

Sepulveda, Patricio V. ;

Bush, Ernest D. ;

Baar, Keith .

CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2015, 42 (01) :1-13

← 1 2 →